Boryung to build W20 billion cGMP plant

Published: 2009-08-19 06:56:00

Updated: 2009-08-19 06:56:00

Boryung Pharm said on August 14 it will invest 20 billion won to build a new cGMP plant producing the raw materials of fimasartan, a novel, non-peptide angiotensin II receptor antagonist and other finished products.

The plant will be built on some 6,863 square meters of land in Ansan of Kyungg...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK